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Context: Activating transcription factor 6 (ATF6) is critical for ini-
tiation and full activation of the unfolded protein response. An as-
sociation between genetic variation in ATF6 and type 2 diabetes
(DM2) was recently reported in Pima Indians.
Objectives: To investigate the broader significance of this associa-
tion for DM2, replication studies in distinct ethic populations are
required.We investigatedATF6 for its associationwithDM2 inDutch
Caucasians.
Design/Setting: A genetic association study was conducted at an
academic research laboratory.
Study Participants: Two independent Dutch cohorts were studied.
Cohort 1 (n 154) was used to evaluate genetic variation in the ATF6
gene in relation to glucose homeostasis in the general population.
Cohort 2 (n  798) consisted of patients with DM2, impaired glucose
tolerance, impaired fasting glucose, and normoglycemic control sub-
jects, and was used to investigate ATF6 polymorphisms for their
contribution to disturbed glucose homeostasis and DM2.
Main Outcome Measures: There were 16 tag single nucleotide
polymorphisms genotyped in all subjects of both cohorts. Those single
nucleotide polymorphisms included three nonsynonymous coding
variants and captured all common allelic variation of ATF6.
Results: Our data show that common ATF6 variants are associated
with elevated glucose levels in the general population (cohort 1, P 
0.005–0.05). Furthermore, the majority of these variants, and haplo-
types thereof, were significantly associated with impaired fasting glu-
cose, impaired glucose tolerance, and DM2 (cohort 2, P  0.006–0.05).
Associated variants differ from those identified in Pima Indians.
Conclusions: Our results strengthen the evidence that one or more
variants in ATF6 are associated with disturbed glucose homeostasis
and DM2. (J Clin Endocrinol Metab 92: 2720–2725, 2007)
EVIDENCE IS EMERGING in literature that the endo-plasmic reticulum (ER) may represent a major link
between obesity, insulin resistance, -cell function, and type
2 diabetes (DM2) (1–5). Obesity generates stress conditions
that increase the demand on the ER. To cope with this stress,
cells initiate a signal transduction pathway called the ER-
stress response, or unfolded protein response (UPR). Acti-
vation of the UPR is regulated by three ER stress sensors:
protein kinase R-like ER kinase (PERK), inositol requiring 1
(IRE1), and activating transcription factor 6 (ATF6) (6). Ac-
tivation of PERK, IRE1, andATF6 is under control of amaster
UPR regulator, the ER chaperone protein BiP/Grp78. The
PERK and IRE1 initiated pathways of the UPR play an im-
portant role in DM2 through effects on -cell function and
peripheral insulin signaling, respectively (1, 3).
Within the framework of a previous gene expression study
(7), we found a positive significant correlation between in
vitro mRNA levels of BiP/Grp78 in cultured Epstein-Barr
virus-transformed lymphoblasts and the fasting plasma glu-
cose levels that had been measured in the corresponding
subjects, in vivo. Therefore,we hypothesized that the intrinsic
cellular UPR capacity may partially determine a subject’s
plasma glucose level and, moreover, that genetic variation in
UPR genes may contribute to DM2. An excellent candidate
gene to link UPR capacity to DM2 is ATF6. First, ATF6 is
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essential for full activation of the UPR and considered as a
critical UPR initiator in mammalian cells (8). Second, ATF6
induces expression of BiP/Grp78 both directly and indirectly
via activation of X-box binding protein 1. Third, ATF6maps
to chromosome 1q23.3, the most replicated chromosomal
locus for DM2 (9). While preparing this manuscript,
Thameem et al. (10) reported an association of ATF6 with
DM2 in Pima Indians. To investigate the broader significance
of this association for DM2, replication studies in additional
populations are required. In the present study, we investi-
gatedATF6 as a positional and functional candidate gene for
disturbed glucose homeostasis and DM2.
Subjects and Methods
Study populations
Two independent Dutch cohorts, comprising a total of 952 Caucasian
subjects, were used to investigate the genetic association between poly-
morphisms in the ATF6 gene, disturbed glucose homeostasis, and DM2.
The first cohort (n  154) was recruited as spouses of hyperlipidemic
patients, collected within the framework of a family study on the ge-
netics of familial combined hyperlipidemia. These subjects, not selected
in any way, represented the general population and exhibited the fol-
lowing clinical characteristics: 42% males, age 51  11 yr, body mass
index (BMI) 25.4  3.9 kg/m2, fasting blood glucose 4.9  0.7 mmol/
liter, fasting plasma insulin 6.1 5.4 U/ml, and homeostasis model of
assessment insulin resistance 1.4 1.5. In this cohort, 137 subjects (89%)
had normal fasting glucose levels, 16 subjects (10.5%) had impaired
fasting glucose (IFG) levels, and one subject (1%) had DM2. No DNA
was available for three subjects, leaving 151 subjects available for anal-
yses. This cohort was used to explore the genetic variation in the ATF6
gene in relation to glucose homeostasis in the general population.
A second independent Dutch cohort (n  798) that consisted of 211
DM2 patients, 208 IFG/impaired glucose tolerance (IGT) subjects, and
379 normoglycemic controls was used to investigate ATF6 polymor-
phisms for their contribution to disturbed glucose homeostasis and
DM2. This case control cohort was collected as described previously (11,
12). Briefly,more than 2700 subjectswith one ormore cardiovascular risk
factors, including hypertension, BMI more than 25 kg/m2, a positive
family history for DM2, or a history of gestational diabetes, were
screened for DM2. Exclusion criteria were the use of medication that
affects glucose metabolism and non-Caucasian ethnicity. All newly di-
agnosed subjects with IFG, IGT, or DM2, and a random selection of 379
normoglycemic control subjects were included in the present study.
Characteristics of this cohort are provided in Table 1. The Human In-
vestigation Review Committee of the Academic Hospital Maastricht
approved the study protocol, and all subjects gave written informed
consent.
Single nucleotide polymorphism (SNP) selection
and genotyping
SNP selectionwas designed to achieve 100% coverage of the common
genetic variation [minor allele frequency (MAF)  10%] of the ATF6
gene, including 3-kb upstream and downstream this locus. Using the
HapMap database (http://www.hapmap.org/index.html.en), 13 tag
SNPs were selected for genotyping. One tag SNP (SNP4) was located in
an exon and caused an amino acid substitution. In addition to the
selection of 13 SNPs by the tagging process, three additional SNPs were
selected for their potential direct functional effect: SNP3 and SNP5 for
their location in exons, causing an amino acid substitution, and SNP15
for its location in the 3 untranslated region. In total, 16 SNPs were
genotyped in 952 subjects. Genotyping was done using the TaqMan
7900HT (Applied Biosystems, Foster City, CA).
Statistical analyses
Power calculations were performed using the genetic power cal-
culator of Purcell et al. (13) (http://pngu.mgh.harvard.edu/pur-
cell/gpc/). Assuming a disease prevalence of 0.1, a genotype relative
risk of 1.1 and 2.3 [the calculated relative risks of Aa and AA, re-
spectively, in a previous study (10)], and an allele frequency of 0.2 [the
frequency of the ATF6 risk allele, previously associated with DM2
(10)], the case control sample afforded an estimated power of 71% at
P  0.05. Linkage disequilibrium statistics were analyzed by
Haploview software (14). Haplotypes were constructed using the
program SNPHAP (http://www-gene.cimr.cam.ac.uk/clayton/
software). Analyses of variance and Student’s t tests were used to test
polymorphisms in the ATF6 gene for association with plasma glucose
levels. Odds ratios and P values for case control analyses were cal-
culated using logistic regression analyses in which “allele” was pa-
rameterized in the model as a dichotomous variable. Adjustments for
age, gender, and BMI were done by including these variables in the
logistic regression model.
Results
The intrinsic capacity of the UPR may influence fasting
plasma glucose levels
In a previous gene expression experiment, designed to
study the genetic background of combined hyperlipid-
emia, we cultured Epstein-Barr virus-transformed lym-
phoblast cells from 12 hyperlipidemic patients and 12
normolipidemic controls (7). To explore further this data
set in relation to glucose homeostasis, we measured
plasma glucose levels in these subjects and reanalyzed
transcript levels in relation to this previously unstudied
trait. One subject with a fasting plasma glucose more than
3 sds of the mean was excluded, leaving 23 subjects for
analyses. Subjects exhibited the following characteristics:
age 50  9 yr, 11 males/12 females, and fasting plasma
glucose levels 5.3  0.8 mmol/liter. A complete clinical
characterization of these subjects has been provided in an
article by Morello et al. (7).
We observed a strong positive correlation (r  0.57; P 
0.004) between in vitro mRNA levels of BiP/Grp78 and the
fasting plasma glucose levels in the corresponding subjects,
in vivo. This correlation is very unlikely the result of the
well-known response of Bip/Grp78 expression to glucose
(15) because all cells had been cultured for several weeks
under isoglycemic and standardized conditions. This obser-
vation led to the hypothesis that the intrinsic UPR capacity
may partially determine fasting plasma glucose levels and
that UPR genes may be involved in glucose homeostasis.
Therefore, we performed a genetic association study with
ATF6, a key gene of the UPR, and transcriptional regulator
of Bip/Grp78.
Genetic variation in the ATF6 gene
The ATF6 gene consists of 16 exons that span approxi-
mately 193-kb genomic DNA. The gene structure of ATF6,
the frequencies of the minor alleles for each SNP, and the
pairwise correlation of alleles between various SNPs are
depicted in Fig. 1 [data for cohort 2 (n  798)]. Genotype
TABLE 1. Characteristics of cohort 2
Trait NGT IFG/IGT DM2
No. (male/female) 379 (222/157) 208 (125/83) 211 (144/67)
Age (yr) 58  7 58  7 60  7
BMI (kg/m2) 27.4  3.8 29.3  4.2 30.7  4.4
Data are means  SD, unless otherwise indicated. NGT, Normal
glucose tolerance.
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success rate was more than 97% for all 16 genotyped SNPs.
All SNPs were in Hardy-Weinberg equilibrium.
ATF6 polymorphisms are associated with fasting plasma
glucose levels in the general population (cohort 1)
First, we investigated whether genetic variation in the
ATF6 gene was associated with fasting glucose levels in the
first cohort from the general population (Table 2). ANOVAs
revealed a significant association of SNPs 9, 12, 13, and 15
with fasting glucose levels in this cohort (P  0.018–0.053).
Further analyses under a dominant genetic model strength-
ened the evidence for association with these SNPs (P 
0.005–0.015). In addition, SNP3 and SNP6 were borderline
significant under a dominant genetic model. These data sug-
gest that ATF6 polymorphisms modulate plasma glucose
levels in the general population.
ATF6 polymorphisms are associated with disturbed glucose
homeostasis and DM2 (cohort 2)
Next, to test the hypothesis that variation in ATF6 con-
tributes to disturbed glucosemetabolism andDM2,we geno-
typed all selected SNPs in the second cohort (n  798),
comprising 211 patients with DM2, 208 subjects with IFG/
IGT, and 379 normoglycemic controls (Table 3). In line with
results from the first cohort, prevalence of the minor allele of
SNPs 12, 13, and 15 was significantly increased in cases
compared with control subjects (P  0.033–0.051). Further-
more, SNP6, which showed a trend for association in cohort
1, was significantly different in cases and controls of cohort
2 (unadjusted P  0.027). For SNP3 and SNP9, we were not
able to confirm the significant association of cohort 1. Sta-
tistical analyses using alternative genetic models (genotype,
dominant, and recessive) support these findings (P  0.01–
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FIG. 1. Genetic structure of the ATF6 gene, including the 16 genotyped SNPs and MAFs. Dashed boxes represent the promotor region and the
3 untranslated region. Exons are represented by vertical lines. MAFs of the genotyped SNPs are shown in the gray horizontal bar. The shade
of the diamonds represents the pairwise r2 between the two SNPs defined by the top left and the top right sides of the diamond. Shading
represents the magnitude of pairwise r2, with at the extremes white reflecting very low r2 (0.20) and black reflecting very high r2 (0.80).
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0.05) (supplemental Table 1, published as supplemental data
on The Endocrine Society’s Journals Online web site at
http://jcem.endojournals.org).
Haplotype analysis
Haplotype analysis provided similar results. Statistical re-
construction of haplotypes comprising the four significantly
associated SNPs (6, 12, 13, and 15) identified three common
haplotypes, which together accounted for 99% of observed
haplotypes in cases and controls (Table 4). We identified an
“at risk” haplotype (GGAG), with higher prevalence in sub-
jects with DM2, IGT, and IFG comparedwith controls [14.4%
vs. 9.9%; odds ratio 1.54; 95% confidence interval 1.13–2.09;
P  0.006]. The opposite AAGA haplotype showed a trend
for higher prevalence in control subjects compared with sub-
jects with disturbed glucose homeostasis (76.4% vs. 72.2%;
odds ratio 0.80; 95% confidence interval 0.64–1.01;P 0.056).
It is noteworthy that stratified analyses showed that the
prevalence of the GGAG-risk haplotype was significantly
increased in both subjects with IFG or IGT (odds ratio 1.59;
P  0.011) as well as in patients with fully developed DM2
(odds ratio 1.48; P  0.036).
Discussion
ATF6 is essential for full activation of the UPR and con-
sidered a critical UPR initiator in mammalian cells (8). In the
present study, we show that ATF6 polymorphisms and hap-
lotypes are associated with disturbed glucose homeostasis
and DM2 in Dutch Caucasians. While this work was in
progress, a genetic association between amino acid variants
TABLE 2. Associations (genotype effects) of ATF6 polymorphisms with fasting plasma glucose levels in the general population (cohort 1)
SNP Genotype n Glucose  SD (mmol/liter) P value genotype P value recessive P value dominant
SNP 1 (rs 4657101) A/A 94 4.85  0.54
A/C 34 5.00  0.89 0.501 0.938 0.276
C/C 12 4.90  0.51
SNP 2 (rs 7553368) T/T 70 4.95  0.68
T/C 56 4.90  0.73 0.789 0.559 0.584
C/C 16 4.82  0.61
SNP 3 (rs 1058405) A/A 78 5.00  0.79
A/G 53 4.78  0.57 0.123 0.331 0.043
G/G 13 4.72  0.45
SNP 4 (rs 2070150) G/G 125 4.88  0.65
G/C 17 5.05  0.81 0.357 0.297 0.232
C/C 1 5.60
SNP 5 (rs 16846208) C/C 124 4.89  0.67
C/T 16 5.08  0.83 0.356 0.323 0.214
T/T 1 5.6
SNP 6 (rs 4579731) A/A 102 4.84  0.58
A/G 38 5.10  0.91 0.127 0.657 0.057
G/G 1 4.60
SNP 7 (rs 2134697) T/T 76 4.81  0.58
T/C 63 4.99  0.83 0.306 0.625 0.125
C/C 6 5.03  0.45
SNP 8 (rs 1503815) C/C 115 4.89  0.72
C/T 31 4.89  0.50 0.838 0.552 0.912
T/T 1 5.3
SNP 9 (rs 2340721) A/A 61 4.73  0.51
C/A 73 5.03  0.77 0.033 0.567 0.009
C/C 14 5.01  0.75
SNP 10 (rs 11581364) G/G 53 4.93  0.59
G/T 66 4.89  0.69 0.857 0.664 0.636
T/T 22 4.84  0.54
SNP 11 (rs 7554023) A/A 107 4.94  0.65
A/G 28 4.87  0.88 0.630 0.397 0.441
G/G 8 4.71  0.29
SNP 12 (rs 10918215) A/A 80 4.77  0.53
A/G 56 5.08  0.81 0.025 0.390 0.006
G/G 10 5.09  0.83
SNP 13 (rs 7514053) G/G 78 4.76  0.53
G/A 56 5.08  0.81 0.018 0.376 0.005
A/A 10 5.09  0.83
SNP 14 (rs 10918243) T/T 64 4.98  0.76
T/C 61 4.91  0.65 0.260 0.120 0.304
C/C 18 4.68  0.48
SNP 15 (rs 13401) A/A 82 4.77  0.53
A/G 57 5.05  0.82 0.053 0.577 0.015
G/G 12 5.00  0.79
SNP 16 (rs 3795649) C/C 57 4.94  0.73
C/T 62 4.91  0.66 0.849 0.616 0.657
T/T 26 4.85  0.67
P values in bold reflect statistical significance.
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in ATF6 and DM2 was reported in Pima Indians (10). Ad-
ditional replication studies are strongly required to validate
these findings and evaluate their broader significance for
predisposition to DM2 in different ethnic populations.
In the present study, we identified polymorphisms in the
ATF6 gene, significantly associated with fasting glucose lev-
els in a cohort representative for the general population, and
with disturbed glucose homeostasis/DM2 in a second co-
hort, ascertained for IFG, IGT, and DM2. Allele frequencies
from associated SNPs 12, 13, and 15 were slightly higher in
subjects from the general population in cohort 1 (26%) than
in normoglycemic control subjects in cohort 2 (23%). Differ-
ent recruitment criteria and statistical variance may account
for this difference: control subjects in cohort 2 are nondia-
betic, verified by an oral glucose tolerance test, whereas
subjects from the general population in cohort 1 may include
some undetected DM2 patients.
The associated SNPs in this study were all located in non-
coding regions of the ATF6 gene. SNPs 6, 12, and 13 map to
introns, whereas SNP15 locates to the 3 untranslated region.
It is noteworthy that SNP15 is in direct vicinity (11 base pairs
in 5direction) of anAATAAA-poly-adenylation sequence in
the 3 untranslated region. This recognition site is involved
in polyadenosine tail formation, which protects the mRNA
molecule from exonucleases, and is important for transcrip-
tion termination, for export of the mRNA from the nucleus,
and for translation.
Three known exonic variants have beendescribed inATF6:
Pro[145]Ala, Ser[157]Pro, and Met[67]Val. In Pima Indians,
the amino acid variants Pro[145]Ala and Ser[157]Pro poly-
morphism showed an association (P  0.05) with DM2 (10).
These amino acid substitutions (SNP4 and SNP5, respec-
tively, in our study) were not significantly associated with
fasting glucose levels in our first cohort, or with disturbed
glucose homeostasis and DM2 in the second cohort. The
negative result is very unlikely due to a lack of statistical
power because allele frequencies were identical in cases and
controls, not even revealing a trend toward significance
(SNP4 adjusted P 0.97; SNP5 adjusted P 0.99). The third
known ATF6 amino acid variant, Met[67]Val (SNP3), which
was not previously found associated with DM2 in Pima
Indians (10), was associated with fasting plasma glucose
TABLE 4. ATF6 haplotype distribution in cases (DM2, IFG, and
IGT) and normoglycemic control subjects
Haplotype Control subjects (%) Cases (%) P value
AAGA 76.4 72.2 0.056
AGAG 12.5 12.6 0.944
GGAG 9.9 14.4 0.006
Rare 1.2 0.7 0.330
Total 100 100
Haplotype frequencies for the four significantly associated SNPs in
Table 2 were estimated with SNPHAP. Of haplotypes, 97% were
estimatedwith a probability 97%.P values in bold reflect statistical
significance.
TABLE 3. ATF6 SNP allele frequencies in cases (DM2, IFG, and IGT) and normoglycemic control subjects (cohort 2)
SNP rs no. No. of alleles Affected status No. of allele 1 (%) No. of allele 2 (%) P value P value adjusteda
SNP 1 (rs 4657101) 1570 Controls 551 (0.74) 197 (0.26) 0.680 0.805
Cases 613 (0.75) 209 (0.25)
SNP 2 (rs 7553368) 1570 Controls 506 (0.68) 244 (0.32) 0.235 0.237
Cases 576 (0.70) 244 (0.30)
SNP 3 (rs 1058405) 1582 Controls 527 (0.70) 227 (0.30) 0.887 0.855
Cases 576 (0.70) 252 (0.30)
SNP 4 (rs 2070150) 1578 Controls 693 (0.92) 61 (0.08) 0.812 0.974
Cases 760 (0.92) 64 (0.08)
SNP 5 (rs 16846208) 1584 Controls 693 (0.92) 61 (0.08) 0.780 0.992
Cases 766 (0.92) 64 (0.08)
SNP 6 (rs 4579731) 1564 Controls 656 (0.89) 82 (0.11) 0.027 0.037
Cases 703 (0.85) 123 (0.15)
SNP 7 (rs 2134697) 1576 Controls 590 (0.79) 162 (0.21) 0.074 0.082
Cases 615 (0.75) 209 (0.25)
SNP 8 (rs 1503815) 1566 Controls 672 (0.90) 76 (0.10) 0.929 0.985
Cases 736 (0.90) 82 (0.10)
SNP 9 (rs 2340721) 1584 Controls 519 (0.69) 235 (0.31) 0.180 0.136
Cases 545 (0.66) 285 (0.34)
SNP 10 (rs 11581364) 1574 Controls 458 (0.61) 290 (0.39) 0.133 0.165
Cases 536 (0.65) 290 (0.35)
SNP 11 (rs 7554023) 1574 Controls 608 (0.81) 140 (0.19) 0.729 0.730
Cases 677 (0.82) 149 (0.18)
SNP 12 (rs 10918215) 1578 Controls 580 (0.77) 170 (0.23) 0.039 0.043
Cases 603 (0.73) 225 (0.27)
SNP 13 (rs 7514053) 1592 Controls 575 (0.77) 169 (0.23) 0.051 0.058
Cases 606 (0.73) 242 (0.27)
SNP 14 (rs 10918243) 1576 Controls 481 (0.64) 273 (0.36) 0.935 0.758
Cases 526 (0.64) 296 (0.36)
SNP 15 (rs 13401) 1596 Controls 586 (0.77) 172 (0.23) 0.033 0.042
Cases 609 (0.73) 229 (0.27)
SNP 16 (rs 3795649) 1570 Controls 439 (0.59) 307 (0.41) 0.084 0.143
Cases 520 (0.63) 304 (0.37)
P values in bold reflect statistical significance.
a Adjusted for age, gender, and BMI.
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levels in cohort 1, but again, allele frequencies were not
significantly different between cases and controls in cohort
2. Further genetic research and functional studies are needed
to establish which SNP(s) in the ATF6 gene are functionally
responsible for the observed associations in both popula-
tions. Althoughwe do not provide a formal replication of the
genetic association in Pima Indians, in which replication is
defined by same allele, same genetic model, and same phe-
notype, our data do, however, confirm and extend the nature
of their observations, and emphasize that the ATF6 gene is
also relevant for susceptibility to disturbed glucose ho-
meostasis and DM2 in Dutch Caucasians.
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